Squamous cell carcinoma of the penis and of the cervix, vulva and vagina in spouses: is there any relationship? An epidemiological study from Norway, 1960-92

Iversen, T.; Tretli, Steinar; Johansen, Anders; Holte, Thea

doi:10.1038/bjc.1997.441

Cited by 26 publications

(19 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study covers the years 1999-2012 and is to some extent a more detailed continuation of Gawelko et al's research. Our presented results for the Polish population are consistent with data shown by Iversen et al [17], who reported the age-adjusted vulvar cancer incidence rate in Norway to have been between 0.9 and 1.1 for the years 1956-1990. Similar age-standardised vulvar incidence rates from 1.0 to 1.3 were stated in Switzerland in the period 1988-1992 [1].…”

Section: Discussionsupporting

confidence: 82%

“…Additionally, there is a lack of information concerning the type of treatment patients receive, and there are no data on the 5-year survival rate and the recurrence-free period. Also, a 14-year study period cannot be considered as long; however, it is relevant for statistical analysis and comparable with similar studies with a median study period of 18.5 years, ranging from 4 to 39 years [1,4,6,17,18,19,33]. A longer-term retrospective analysis was unfortunately impossible due to previously explained missing data for the years 1997-1998.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Primary Vulvo-Vaginal Cancers: Trends in Incidence and Mortality in Poland (1999-2012)

Banaś

Pitynski

Jach

et al. 2015

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: The aim of this study was to determine the incidence, mortality rates and trends of vulvar and vaginal cancers in Poland. Methods: Data were retrieved from the Polish National Cancer Registry. Age-standardised rates (ASRs) of cancer incidence and mortality were calculated by direct standardisation, and joinpoint regression was performed to describe the trends using the average annual percent change (AAPC). Results: From 1999 to 2012, the number of diagnosed cases of vulvar cancer was 5,958, and the ASRs of incidence varied from 0.99 to 1.18, with a significant trend towards a decrease (AAPC -0.78; p < 0.05). The ASR of mortality varied from 0.39 to 0.62, with a slight but insignificant increase in trend (AAPC 0.72; p > 0.05). The ASR of vaginal cancer incidence varied from 0.21 to 0.31, while the ASR of mortality ranged from 0.09 to 0.22. This study also proved a significantly falling trend in vaginal cancer mortality (AAPC -4.69; p < 0.05) and a decreasing trend in vaginal cancer incidence (AAPC -1.67; p > 0.05). Conclusion: The rarity of vulvar and vaginal cancers as well as the decline in their incidence rates should not discourage further research on the epidemiology and treatment of these conditions.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Primary Vulvo-Vaginal Cancers: Trends in Incidence and Mortality in Poland (1999-2012)

Banaś

Pitynski

Jach

et al. 2015

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…While keeping the incidence of penile cancer in noncircumcised men consistent with the rate reported in northern Europe (lifetime risk of 1 in 1149), [115][116][117] the rate in circumcised men was reduced using the odds ratio and 95% confidence intervals determined by Maden and others. 15 The cost of treating penile cancer was estimated at $25,000.…”

Section: Penile Cancermentioning

confidence: 66%

A Cost-Utility Analysis of Neonatal Circumcision

Howe

2004

Med Decis Making

View full text Add to dashboard Cite

A cost-utility analysis, based on published data from multiple observational studies, comparing boys circumcised at birth and those not circumcised was undertaken using the Quality of Well-being Scale, a Markov analysis, the standard reference case, and a societal perspective. Neonatal circumcision increased incremental costs by $828.42 per patient and resulted in an incremental 15.30 well-years lost per 1000 males. If neonatal circumcision was cost-free, pain-free, and had no immediate complications, it was still more costly than not circumcising. Using sensitivity analysis, it was impossible to arrange a scenario that made neonatal circumcision cost-effective. Neonatal circumcision is not good health policy, and support for it as a medical procedure cannot be justified financially or medically.

show abstract

“…Reports addressing the association of penile carcinoma with cervical carcinoma in sexual partners or with herpetic infections are conflicting [9][10][11].…”

Section: Aetiology and Risk Factorsmentioning

confidence: 98%